Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral propranolol for prevention of severe retinopathy of prematurity
IRCT20101018004961N12Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of propranolol in retinopathy of prematurity (ROP) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoints: Rate of recovery from retinopathy of prematurity, Need for intravitreal bevacizumab injection and 2 more. Started Jul 2021; status: completed.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on IRCT20101018004961N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20101018004961N12.